O USO DA TIRZEPATIDA PARA O TRATAMENTO DA OBESIDADE.

• DOI: https://doi.org/10.22533/at.ed.679122520061

• Palavras-chave: Tirzepatida; Mounjaro; Obesidade, GLP-1, GIP

• Keywords: Tirzepatide; Mounjaro; Obesity, GLP-1, GIP

• Abstract: Obesity remains a persistent challenge for global public health, requiring integrated and innovative therapeutic strategies. Recent evidence has highlighted tirzepatide as a novel pharmacological option, acting synergistically on both GIP and GLP-1 receptors. This dual mechanism enhances glycemic control and induces significant weight loss, surpassing the outcomes observed with therapies based solely on GLP-1 receptor agonists. Literature reviews and clinical studies report additional benefits of tirzepatide, including improvements in lipid profile, blood pressure, and insulin sensitivity. Although associated with gastrointestinal side effects, tirzepatide is generally well tolerated and considered safe. Given its superior efficacy, tirzepatide emerges as a promising strategy in the treatment of obesity.